Drugs |
Specialties
| Education
| Points

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

Country

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Search

Pharmacy

Medical News
Case Studies
CME
Clinical Review
Practice Insights
Patient Resources
Drug Updates

Special Reports

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

China
Hong Kong
India
Indonesia
Malaysia
Myanmar
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand

Drugs |
Specialties
| Education
| Points

Home News Conferences Special Reports Multimedia

Medical News
Case Studies
CME
Clinical Review
Practice Insights
Patient Resources
Drug Updates

Product Highlight - QTERN

29 Nov 2019

• Superior HbA1c reduction vs DPP4i +Met or SGLT2i +Met¹

• Nearly 2x patients achieved HbA1c <7%¹

• Established safety profile of DPP4i with additional benefits of SGLT2i^3,5-8

• Extends oral therapy with a once daily tablet^4-7

References:
1. Rostenstock J, et al. Diabetes Care 2015; 38(3):376·383.
2. T. Vilsboll, et al. Dapagliflozin plus Saxagliptin shows noninferior HbA1c reductions vs insulin Glargine in patients with Type 2 Diabetes Inadequately.
3. Qtern Malaysia Prescribing Information, AstraZeneca, 2019.
4. Lokhandwala T, et al. J Med Econ. 2016: 19: 203-12.
5. Del Prato S, et al. Diabetes Obes Metab 2018; 20: 1542·1546.
6. Matthaei S, et al. Diabetes Care. 2015: 38: 2018-2024.
7. Bailey CJ, et aI. Lancet 2010; 37: 2233-33.
8. Del Prato S, et al. Diabetes Obes Metab 2015;17: 581-90.

Editor's Recommendations

Pharmacy

Specialties

Multidisciplinary
Cardiology
Dermatology
Endocrinology
Gastroenterology
Hepatology
Infectious Diseases
Neurology
Obstetrics & Gynaecology
Oncology
Ophthalmology
Paediatrics
Psychiatry
Respirology
Rheumatology
Urology
Pharmacy

News

Medical News
Case Studies
CME
Clinical Review
Practice Insights
Patient Resources
Drug Updates

Conferences

Conferences Report

More Services

Drugs
Specialties
Education
Points
Subscribe

About

MIMS Corporate
Term of Use
Privacy Policy
Feedback

Connect With MIMS

Copyright © 2023 MIMS Pte Ltd. All rights reserved.